Evidence map›Paper›PMID 32847838›Full record

Trial reportESMO open2020

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

Robin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Luigi Bolondi, Stephen L Chan, Ho Yeong Lim, Ari D Baron, Francis Parnis, Jennifer Knox and 8 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01908426 (A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib), which is not on this map. Cited by 59 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 5 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01908426 phase3completednot on this map

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

TypeinterventionalSponsorExelixisRan2013 to 2021Enrolled707ConditionsHepatocellular CarcinomaArmsCabozantinib tablets, Placebo tablets
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 5 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Advancements in second-line treatment research for hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 17 institutions in 9 countries.

Robin Kate KelleyUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA katie.kelley@ucsf.edu.
Baek-Yeol RyooAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Philippe MerleGroupement Hospitalier Lyon Nord, Lyon, France.
Joong-Won ParkNational Cancer Center, Goyang, Republic of Korea.
Luigi BolondiDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Stephen L ChanDepartment of Clinical Oncology, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong.
Ho Yeong LimSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
Ari D BaronCalifornia Pacific Medical Center, San Francisco, California, USA.
Francis ParnisAdelaide Cancer Centre, Adelaide University, Kurralta Park, South Australia, Australia.
Jennifer KnoxPrincess Margaret Hospital, Toronto, Ontario, Canada.
Stéphane CattanCHRU Lille, Lille, France.
Thomas YauQueen Mary Hospital, Hong Kong, China.
Julie C LougheedMedical Affairs, Exelixis Inc, Alameda, California, USA.
Steven MilweeClinical Development, Exelixis Inc, Alameda, California, USA.
Anthony B El-KhoueiryUSC Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Ann-Lii ChengNational Taiwan University Hospital, Taipei, Taiwan.
Tim MeyerRoyal Free Hospital, London, UK.
Ghassan K Abou-AlfaMemorial Sloan Kettering Cancer Center, New York, United States.
Exelixis (United States) · USCalifornia Pacific Medical Center · USCentre Hospitalier Universitaire de Lille · FRChinese University of Hong Kong · CNHôpital Lyon Sud · FRMemorial Sloan Kettering Cancer Center · USNational Cancer Center · KRNational Taiwan University Hospital · TWPrincess Margaret Cancer Centre · CAQueen Mary Hospital · CNSamsung Medical Center · KRUlsan College · KRUniversity College London · GBUniversity of Adelaide · AUUniversity of Bologna · ITUniversity of California, San Francisco · USUSC Norris Comprehensive Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cancer Research UK 26813NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveIn the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated cabozantinib in patients who had received sorafenib as the only prior systemic therapy.

methodsCELESTIAL randomised (2:1) patients with advanced HCC and Child-Pugh class A liver function to treatment with cabozantinib (60 mg daily) or placebo. Eligibility required prior treatment with sorafenib, and patients could have received ≤2 prior systemic regimens. The primary endpoint was OS. Outcomes in patients who had received sorafenib as the only prior therapy were analysed by duration of prior sorafenib (<3 months, 3 to <6 months and ≥6 months).

resultsOf patients who had received only prior sorafenib, 331 were randomised to cabozantinib and 164 to placebo; 136 patients had received sorafenib for <3 months, 141 for 3 to <6 months and 217 for ≥6 months. Cabozantinib improved OS relative to placebo in the overall second-line population who had received only prior sorafenib (median 11.3 vs 7.2 months; HR=0.70, 95% CI 0.55 to 0.88). This improvement was maintained in analyses by prior sorafenib duration with longer duration generally corresponding to longer median OS-median OS 8.9 vs 6.9 months (HR=0.72, 95% CI 0.47 to 1.10) for prior sorafenib <3 months, 11.5 vs 6.5 months (HR=0.65, 95% CI 0.43 to 1.00) for 3 to <6 months and 12.3 vs 9.2 months (HR=0.82, 95% CI 0.58 to 1.16) for ≥6 months. Cabozantinib also improved PFS in all duration subgroups. Safety data were consistent with the overall study population.

conclusionCabozantinib improved efficacy outcomes versus placebo in the second-line population who had received only prior sorafenib irrespective of duration of prior sorafenib treatment, further supporting the utility of cabozantinib in the evolving treatment landscape of HCC. CLINICAL TRIAL NUMBER: NCT01908426.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overAnilidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedPyridinesSorafenibYoung AdultAnilidesAntineoplastic AgentscabozantinibPyridinesSorafenibcabozantinibhepatocellular carcinomasorafenibtyrosine kinase inhibitor

Identifiers

PMID32847838
PMCPMC7451459
OpenAlexW3080424252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.